Janus Henderson Group’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $48.7M | Buy |
147,089
+10,664
| +8% | +$3.63M | 0.02% | 419 |
|
|
2025
Q4 | $54.3M | Buy |
136,425
+570
| +0.4% | +$252K | 0.02% | 395 |
|
|
2025
Q3 | $61.9M | Sell |
135,855
-14,566
| -10% | -$5.93M | 0.03% | 366 |
|
|
2025
Q2 | $49M | Sell |
150,421
-31,228
| -17% | -$8.64M | 0.02% | 391 |
|
|
2025
Q1 | $48.8M | Sell |
181,649
-28,431
| -14% | -$7.31M | 0.03% | 381 |
|
|
2024
Q4 | $49.4M | Sell |
210,080
-9,257
| -4% | -$2.43M | 0.03% | 391 |
|
|
2024
Q3 | $60.3M | Sell |
219,337
-30,103
| -12% | -$7.84M | 0.03% | 347 |
|
|
2024
Q2 | $60.6M | Buy |
249,440
+70,486
| +39% | +$11.1M | 0.03% | 344 |
|
|
2024
Q1 | $26.7M | Sell |
178,954
-99,127
| -36% | -$16.5M | 0.01% | 514 |
|
|
2023
Q4 | $53.2M | Sell |
278,081
-15,409
| -5% | -$2.62M | 0.03% | 362 |
|
|
2023
Q3 | $52M | Buy |
293,490
+1,651
| +0.6% | +$315K | 0.03% | 355 |
|
|
2023
Q2 | $55.4M | Sell |
291,839
-7,004
| -2% | -$1.39M | 0.03% | 371 |
|
|
2023
Q1 | $59.9M | Sell |
298,843
-166,545
| -36% | -$35M | 0.04% | 341 |
|
|
2022
Q4 | $111M | Sell |
465,388
-683,620
| -59% | -$146M | 0.08% | 225 |
|
|
2022
Q3 | $230M | Buy |
1,149,008
+699,295
| +155% | +$133M | 0.09% | 219 |
|
|
2022
Q2 | $65.6M | Sell |
449,713
-148,735
| -25% | -$21.1M | 0.05% | 322 |
|
|
2022
Q1 | $97.7M | Buy |
598,448
+97,115
| +19% | +$14.8M | 0.05% | 325 |
|
|
2021
Q4 | $85M | Buy |
501,333
+479,756
| +2,223% | +$89.2M | 0.04% | 394 |
|
|
2021
Q3 | $4.08M | Buy |
21,577
+9,852
| +84% | +$1.85M | ﹤0.01% | 1103 |
|
|
2021
Q2 | $1.99M | Sell |
11,725
-6,458
| -36% | -$946K | ﹤0.01% | 1239 |
|
|
2021
Q1 | $2.57M | Sell |
18,183
-72,072
| -80% | -$10.8M | ﹤0.01% | 1140 |
|
|
2020
Q4 | $11.7M | Sell |
90,255
-72,314
| -44% | -$9.66M | 0.01% | 843 |
|
|
2020
Q3 | $23.7M | Sell |
162,569
-61,092
| -27% | -$8.68M | 0.01% | 671 |
|
|
2020
Q2 | $33.1M | Sell |
223,661
-183,796
| -45% | -$24.8M | 0.02% | 587 |
|
|
2020
Q1 | $44.4M | Buy |
407,457
+353,980
| +662% | +$40.9M | 0.03% | 482 |
|
|
2019
Q4 | $6.16M | Buy |
53,477
+12,938
| +32% | +$1.29M | ﹤0.01% | 1024 |
|
|
2019
Q3 | $3.26M | Buy |
40,539
+13,788
| +52% | +$1.09M | ﹤0.01% | 1106 |
|
|
2019
Q2 | $1.94M | Buy |
26,751
+1,508
| +6% | +$116K | ﹤0.01% | 1153 |
|
|
2019
Q1 | $2.36M | Buy |
25,243
+841
| +3% | +$70.3K | ﹤0.01% | 1102 |
|
|
2018
Q4 | $1.78M | Sell |
24,402
-1,200
| -5% | -$92.3K | ﹤0.01% | 1114 |
|
|
2018
Q3 | $2.24M | Sell |
25,602
-76,900
| -75% | -$7.74M | ﹤0.01% | 1163 |
|
|
2018
Q2 | $10.1M | Sell |
102,502
-401,809
| -80% | -$39.9M | 0.01% | 921 |
|
|
2018
Q1 | $60.1M | Buy |
504,311
+10,692
| +2% | +$1.38M | 0.04% | 512 |
|
|
2017
Q4 | $62.7M | Sell |
493,619
-189,401
| -28% | -$23.8M | 0.04% | 486 |
|
|
2017
Q3 | $80.2M | Buy |
683,020
+15,687
| +2% | +$1.34M | 0.05% | 402 |
|
|
2017
Q2 | $53.2M | Buy |
+667,333
| New | +$42.6M | 0.04% | 499 |
|
|
2017
Q1 | – | Sell |
-3,879
| Closed | -$145K | – | 837 |
|
|
2016
Q4 | $145K | Sell |
3,879
-6,259
| -62% | -$262K | ﹤0.01% | 835 |
|
|
2016
Q3 | $687K | Hold |
10,138
| – | – | 0.01% | 725 |
|
|
2016
Q2 | $562K | Hold |
10,138
| – | – | ﹤0.01% | 740 |
|
|
2016
Q1 | $636K | Hold |
10,138
| – | – | 0.01% | 727 |
|
|
2015
Q4 | $955K | Hold |
10,138
| – | – | 0.01% | 650 |
|
|
2015
Q3 | $814K | Buy |
10,138
+3,879
| +62% | +$431K | 0.01% | 679 |
|
|
2015
Q2 | $750K | Buy |
+6,259
| New | +$748K | 0.01% | 729 |
|
Other funds holding ALNY
VPM
VCM
Janus Henderson Group's ALNY Position: Q1 2026 in Review
Janus Henderson Group increased its Alnylam Pharmaceuticals (ALNY) stake by 7.8% in Q1 2026, buying an estimated $3.63M and bringing the position to 147,089 shares worth $48.7M. The position accounts for 0.02% of the portfolio, ranked #419.
Janus Henderson Group first reported a position in ALNY in Q2 2015 and has held it in 43 quarters since. The position peaked at $230M in Q3 2022. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Janus Henderson Group held 147,089 shares of Alnylam Pharmaceuticals worth $48.7M as of Q1 2026.
- Janus Henderson Group bought 10,664 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $3.63M.
- Alnylam Pharmaceuticals made up 0.02% of Janus Henderson Group's portfolio in Q1 2026, its #419 holding.
- Janus Henderson Group first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 43 quarters since.
- Janus Henderson Group's Alnylam Pharmaceuticals position peaked at $230M in Q3 2022.
- 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.